SPY334.61+0.11 0.03%
DIA278.58-0.33 -0.12%
IXIC10,945.28+35.01 0.32%

Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $173

Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price target from $160 to $173.

Benzinga · 12/24/2019 13:13

Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price target from $160 to $173.